Market Overview

UPDATE: BMO Capital Downgrades Pfizer

Share:
Related PFE
Benzinga's Weekend M&A Chatter
The 5 Best Dow Stocks So Far In 2015
Week Ahead: Busy Economic Calender with FOMC, Earnings (Fox Business)

In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.

Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2014Deutsche BankMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters